Jesus, get the kids costumes ready for Halloween and stop wasting your time here.
215 Viewing!
- Thread starter Anonymous
- Start date
-
- Tags
- None
Ok Ken thanks! By the way nice conference call today. Apparently the market did not like what they heard. Don't worry there will be more conference calls. You can have another go at it.
Ok Ken thanks! By the way nice conference call today. Apparently the market did not like what they heard. Don't worry there will be more conference calls. You can have another go at it.
Now it's over 275 viewing at mid-day--Does anyone work at this company?
Add that to the lack of a product pipeline, poor product performance, massive layoffs.
A buyout isn't far away.
An absolutely avoidable disaster---nothing but greed, lack of insight/strategy and glaring mismanagement since the departure of Roy Vagelos.
(So much for the stock options that expire in February....)
Oh come on, it's human nature. Like a train wreck, no one can look away.
Shares of Merck (MRK) continue to see weakness following the release of a disappointing set of third quarter results. The weak sales of current top-selling drug JANUVIA causes nervousness among investors.
Prospects for increased competition for JANUVIA will most likely undo all the positive impacts of the previously announced job cut programs. Given this continued revenue pressure and the high payout ratio, I remain on the sidelines.
Prospects for increased competition for JANUVIA will most likely undo all the positive impacts of the previously announced job cut programs. Given this continued revenue pressure and the high payout ratio, I remain on the sidelines.